INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 178 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,243,152 | -19.3% | 43,063 | -1.9% | 0.01% | -16.7% |
| Q2 2023 | $2,778,988 | +16.9% | 43,888 | 0.0% | 0.01% | +20.0% |
| Q1 2023 | $2,376,536 | +66.7% | 43,888 | +62.9% | 0.01% | +66.7% |
| Q4 2022 | $1,425,665 | +25.8% | 26,940 | +10.7% | 0.00% | 0.0% |
| Q3 2022 | $1,133,000 | -84.2% | 24,340 | -80.6% | 0.00% | -82.4% |
| Q2 2022 | $7,164,000 | -13.0% | 125,493 | -6.7% | 0.02% | 0.0% |
| Q1 2022 | $8,233,000 | +27.5% | 134,553 | +9.1% | 0.02% | +41.7% |
| Q4 2021 | $6,455,000 | +105.4% | 123,327 | +46.4% | 0.01% | +71.4% |
| Q3 2021 | $3,142,000 | +7.2% | 84,260 | +17.4% | 0.01% | +16.7% |
| Q2 2021 | $2,931,000 | +20.3% | 71,797 | 0.0% | 0.01% | +20.0% |
| Q1 2021 | $2,436,000 | +6.7% | 71,797 | 0.0% | 0.01% | 0.0% |
| Q4 2020 | $2,283,000 | +218.0% | 71,797 | +156.5% | 0.01% | +150.0% |
| Q3 2020 | $718,000 | – | 27,991 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 359,000 | $18,790,000 | 7.62% |
| Velan Capital Investment Management LP | 150,000 | $7,851,000 | 6.09% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 195,000 | $10,206,000 | 4.14% |
| Vantage Consulting Group Inc | 226,670 | $11,864,000 | 3.19% |
| Vahanian & Associates Financial Planning Inc. | 71,742 | $3,755,000 | 3.03% |
| Nicholas Investment Partners, LP | 652,886 | $34,172,000 | 2.16% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $3,199,000 | 1.97% |
| Bellevue Group AG | 3,628,919 | $189,938,000 | 1.96% |
| WASATCH ADVISORS LP | 8,235,171 | $431,029,000 | 1.76% |
| Quantum Private Wealth, LLC | 77,622 | $4,062,000 | 1.54% |